Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lidija Covic

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Thrombosis Research|April 27, 2005
Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosageCarey Kimmelstiel, Jehangir Badar, Lidija Covic, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 4, 2011
Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducinsLeila M Sevigny, Ping Zhang, Andrew Bohm, et al.
Cancer Research|July 23, 2009
Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasisEric Yang, Adrienne Boire, Anika Agarwal, et al.
Circulation. Heart Failure|July 21, 2023
Suppression of Heart Failure With PAR1 Pepducin Technology in a Pressure Overload Model in MiceElizabeth K Fletcher, Njabulo Ngwenyama, Nga Nguyen, et al.
Cancer Research|June 24, 2010
Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapyAnika Agarwal, Sarah L Tressel, Rajani Kaimal, et al.
Circulation. Cardiovascular Interventions|March 3, 2011
Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary interventionCarey Kimmelstiel, Ping Zhang, Navin K Kapur, et al.
JHEP Reports : Innovation in Hepatology|May 6, 2026
Coagulation protease-activated receptor-2 (PAR2) promotes dyslipidemia, obesity and MASLD through repression of the hepatic pioneer factor HNF4αXinru Chen, Nga Nguyen, Susan E Turner, et al.
Cell|April 22, 2009
Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand siteVishal Trivedi, Adrienne Boire, Boris Tchernychev, et al.
Nature Immunology|October 30, 2007
'Role reversal' for the receptor PAR1 in sepsis-induced vascular damageNicole C Kaneider, Andrew J Leger, Anika Agarwal, et al.
Molecular Cancer Therapeutics|September 16, 2008
Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancerAnika Agarwal, Lidija Covic, Leila M Sevigny, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Thrombosis Research|April 27, 2005
Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosageCarey Kimmelstiel, Jehangir Badar, Lidija Covic, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 4, 2011
Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducinsLeila M Sevigny, Ping Zhang, Andrew Bohm, et al.
Cancer Research|July 23, 2009
Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasisEric Yang, Adrienne Boire, Anika Agarwal, et al.
Circulation. Heart Failure|July 21, 2023
Suppression of Heart Failure With PAR1 Pepducin Technology in a Pressure Overload Model in MiceElizabeth K Fletcher, Njabulo Ngwenyama, Nga Nguyen, et al.
Cancer Research|June 24, 2010
Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapyAnika Agarwal, Sarah L Tressel, Rajani Kaimal, et al.
Circulation. Cardiovascular Interventions|March 3, 2011
Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary interventionCarey Kimmelstiel, Ping Zhang, Navin K Kapur, et al.
JHEP Reports : Innovation in Hepatology|May 6, 2026
Coagulation protease-activated receptor-2 (PAR2) promotes dyslipidemia, obesity and MASLD through repression of the hepatic pioneer factor HNF4αXinru Chen, Nga Nguyen, Susan E Turner, et al.
Cell|April 22, 2009
Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand siteVishal Trivedi, Adrienne Boire, Boris Tchernychev, et al.
Nature Immunology|October 30, 2007
'Role reversal' for the receptor PAR1 in sepsis-induced vascular damageNicole C Kaneider, Andrew J Leger, Anika Agarwal, et al.
Molecular Cancer Therapeutics|September 16, 2008
Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancerAnika Agarwal, Lidija Covic, Leila M Sevigny, et al.
Pageof 6